IB Acquisition Corp. (IBAC): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$1.32M

Year ended 2025-09-30

-$1.85M

Trailing 12 months to 2026-06-30

2023-09-30 Operating Cash Flow (USD) 2025-09-30

Period ended	Operating Cash Flow	Change YoY	Source filing
2025-09-30	-$1.32M	n/m	2025-12-29, From 2024-10-01
2024-09-30	-$821.0K	n/m	2025-12-29, From 2023-10-01
2023-09-30	-$207	n/a	2024-12-26, From 2022-10-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Services-Commercial Physical & Biological Research), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Cash Flow	Change YoY
IB Acquisition Corp. (IBAC)	2025-09-30	-$1.32M	n/m
bioAffinity Technologies, Inc. (BIAF)	2025-12-31	-$9.33M	n/m
iSpecimen Inc. (ISPC)	2025-12-31	-$4.24M	n/m
Foxo Technologies Inc. (FOXO)	2025-12-31	-$3.87M	n/m
NRC Health (NRC)	2025-12-31	$26.45M	-23.6%
OneMedNet Corp (ONMD)	2025-12-31	-$7.50M	n/m
MaxCyte, Inc. (MXCT)	2025-12-31	-$34.41M	n/m
Absci Corp (ABSI)	2025-12-31	-$92.92M	n/m
OmniAb, Inc. (OABI)	2025-12-31	-$36.45M	n/m

Compare IBAC, BIAF, ISPC, FOXO side by side · Screen every company in Services-Commercial Physical & Biological Research ↗